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Abstract. The natural history of superficial spreading 
melanomas (SSMs) involves the progression from a radial 
growth phase (RGP) to a vertical growth phase (VGP). 
Currently, a patient's history represents the only method to 
estimate the rate of tumor growth. The present study aimed to 
verify whether the estimated rate of growth (ROG) of SSMs 
with a RGP or VGP exhibited any differences, and to evaluate 
the possible implications for the most important prognostic 
determinants. ROG was quantified as the ratio between Bres-
low's thickness in millimeters (mm) and the time of tumor 
growth in months, defined as the time between the date that 
the patient had first noticed the lesion in which melanoma 
subsequently developed and the date on which the patient first 
felt this lesion changed. A total of 105 patients (58 male and 
47 female) were studied. Of these, 66 had VGP-SSMs, whilst 
39 had RGP‑only SSMs (RGP‑SSMs). No significant differ-
ences in age and gender were observed between these groups. 
The mean Breslow's thickness in patients with VGP‑SSMs 
was significantly greater than in patients with RGP-SSMs 
(0.78±0.68 vs. 0.48±0.22 mm, P=0.0096). Similarly, the 
ROG was observed to be higher in VGP-SSM vs. RGP-SSM 
patients (0.13±0.16 vs. 0.065±0.09 mm/month, P=0.0244). 
In patients with VGP‑SSMs, Breslow's thickness and 
ROG were significantly higher for tumors with a mitotic 
rate of ≥1 mitosis/mm2 compared with those with 
<1 mitosis/mm2 (1.15±0.96 vs. 0.56±0.30 mm, P=0.0005; and 
0.188±0.20 vs. 0.09±0.12 mm/month, P=0.0228, respectively). 
According to these results, two subsets of SSMs exist: The 
first is characterized by the presence of mitosis and a higher 
ROG, while the second exhibits a more indolent behavior and 
is characterized by an RGP only. Given the differences in the 
Breslow's thickness and ROG, clinicians must be aware of the 
possible diagnostic delay in these subsets of melanoma that, 
differently from true nodular melanomas, generally fulfill the 
classical ABCD clinical criteria.
Introduction
Superficial spreading melanoma (SSM) and nodular melanoma 
(NM) exhibit different growth patterns, being characterized 
by slower and faster growth, respectively. The radial growth 
phase (RGP), which is present in SSM and absent in NM, is of 
paramount importance in the classification of melanoma (1‑3). 
The rapid growth of primary melanomas is associated with 
aggressive features and a negative effect on prognosis (4). 
According to the linear model of progression, malignant mela-
nocytes in SSM spread radially prior to invading vertically. 
Clark et al (1) designated this invasion pattern the vertical 
growth phase (VGP), and defined it as the focal formation of a 
dermal nodule within the RGP. Melanomas with a VGP do not 
necessarily indicate NM.
Patient interviews are a useful source of information 
about the growth phase of the tumor (5). The rate of growth 
(ROG), which is defined as the ratio between Breslow's 
thickness in millimetres and the duration of tumor growth in 
months, currently represents the only method to measure the 
growth of a tumor over time, and has been used as an index 
of aggressiveness and even as a prognostic marker in cases of 
melanoma (4-6). The aim of the present study was to evaluate 
the ROG of RGP- and VGP-SSMs in order to assess their 
differences and their impact on the most important prognostic 
determinants (7).
Patients and methods
Patients. Consecutive patients with cutaneous primary 
melanomas treated at the Department of Dermatology of San 
Paolo Hospital (Milan, Italy) between 1st January 2011 and 
30th September 2014 were included in the present study. The 
demographic and clinical characteristics of each patient were 
recorded, including age, gender and site of presentation of the 
tumor. Each patient was asked to recall two dates: T1, the date 
when they had first noticed a lesion at the location where mela-
noma subsequently developed; and T2, the date when they first 
felt that the lesion changed and/or became suspicious. All 
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suspected cases were treated by surgical excision within one 
week from the physician's observation. The inclusion criteria 
for analysis were complete surgical excision and a histologi-
cally confirmed diagnosis of primary SSM melanoma. The 
following exclusion criteria were also applied: Histological 
diagnosis of NM, lentigo maligna, lentigo maligna melanoma 
or in situ melanoma; or inability to provide precise informa-
tion regarding ROG. 
Evaluation of specimens. A dermatopathologist evaluated all 
specimens and reported the histological subtype, Breslow's 
thickness (categorized as <1 or ≥1 mm), ulceration (present or 
absent) and mitotic rate (<1 or ≥1 mitosis/mm2) based on the 
hot‑spot technique (7). The VGP was defined as the presence 
of a cell nest in the dermis larger than the junctional nests and 
composed of tumor cells cytologically different from those 
in the junctional component. SSMs were thus divided into 
groups: Those that exhibited a VGP (VGP-SSMs) and those 
that did not (RGP-SSMs).
Quantification of the kinetics of the visible growth was 
performed using a previously described method (5). According 
to this method, the ROG is defined as the ratio between Breslow's 
thickness in millimetres (mm) and the duration of tumor growth 
in months (T2-T1); this may be used as a surrogate value for 
melanoma kinetics. Patients with de novo melanomas and those 
with melanomas from a pre-existing nevus were distinguished 
according to previously suggested criteria: melanomas were 
considered to be de novo if the T1-T2 interval was ≤5 years, and 
from a pre-existing nevus when this interval was >5 years (5). 
Statistical analysis. The VGP-SSM and RGP-SSM groups were 
compared with regard to differences in ROG and Breslow's 
thickness using the Student's t-test. Statistical analyses were 
performed using SPSS software for Windows (version 15.0; 
SPSS, Inc., Chicago, IL, USA) and P<0.05 was considered to 
indicate a statistically significant difference.
Results
Of the 169 patients contacted by the investigators, 64 (37.8%) 
declined to participate or provided answers that were judged 
to be poorly reliable. The remaining 105 patients (58 male and 
47 female) were hence enrolled in the study. Of these, 66 had 
VGP‑SSM [mean age (± SD), 59.61±16.89 years] and 39 had 
RGP-SSM (mean age, 62.62±16.38 years; P=0.17 vs. VGP-SSM 
group). No significant differences in gender or age between 
the two groups were identified. Table IA reports the results 
obtained from the two groups of patients with melanomas with 
regard to Breslow's thickness and ROG (mm/month), including 
P‑values. Table IB shows the results for the same parameters 
in patients with VGP-SSM only, comparing cases with mitotic 
rates of <1 or ≥1 mitosis/mm2.
Ulceration was observed in only one patient with VGP-SSM. 
The mean Breslow's thickness in patients with VGP‑SSMs was 
significantly greater compared with patients with RGP‑SSMs 
(0.78±0.68 vs. 0.48±022 mm, respectively; P=0.0096). 
Similarly, the ROG differed significantly between VGP‑ and 
RGP-SSM patients (0.13±0.16 vs. 0.065±0.09 mm/month, 
respectively; P=0.0244). Of the cases of VGP-SSM, 24 had a 
mitotic rate of ≥1/mm2, whilst only one RGP-SSM case had a 
mitotic rate ≥1/mm2. In patients with VGP‑SSMs, Breslow's 
thickness was significantly greater when the mitotic rate was 
high (≥1/mm2) compared to the low group (1.15±0.96 vs. 
0.56±0.30 mm, respectively; P=0.0005). The ROG differences 
were also more evident between VGP-SSMs with a high mitotic 
rate and VGP-SSMs with a low mitotic rate (0.188±0.20 vs. 
0.09±0.12 mm/month, respectively; P=0.0228).
Discussion
A previously published study emphasized the importance of 
the presence of two populations of cells in melanoma, which 
were termed slow-growing and fast-growing cells (8). These 
Table I. Breslow's thickness and ROG in patients with VGP‑SSM and RGP‑SSM.
A, Melanoma growth subtypes
Variable Patients (n) Breslow's thickness (mm) ROG (mm/month)
VGP-SSM 66 0.78±0.68 0.13±0.16
RGP-SSM 39 0.48±022 0.065±0.09
P-value  0.0096 0.0244
B, VGP‑SSMs with mitoses
Variable Patients (n) Breslow's thickness (mm) ROG (mm/month)
VGP‑SSM, ≥1 mitosis/mm2 24 1.15±0.96 0.188±0.20
VGP-SSM, <1 mitosis/mm2 42 0.56±0.30 0.09±0.12
P-value  0.0005 0.0228
ROG, rate of growth (millimeters of Breslow/number of months); VGP‑SSM, superficial spreading melanoma with a vertical growth phase; 
RGP‑SSM, superficial spreading melanoma with a radial growth phase only.
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different populations of cells reflect the common observation 
in clinical practice that different types of melanomas grow at 
different rates.
The method described by Grob et al (5), which uses the 
thickness of the lesion and its period of evolution as provided 
by the patient, is the only possible tool to estimate the speed 
of grow of a melanoma. Applying this method, Liu et al (4) 
observed that fast growing melanomas often conform to the 
category of thick melanomas, predominantly observed in the 
elderly. From a clinical perspective, these melanomas are 
symmetrical, not fulfilling the classical ‘Asymmetry, Border, 
Color, Diameter’ (ABCD) rule (9), with atypical clinical 
presentation (i.e., amelanotic and nodular). However, many 
types of melanoma do not fit in these categories (10,11). 
According to the progression model provided for many 
types of melanoma, following a phase of radial growth, the 
loss of cell cycle regulation causes the ability to spread into 
the dermis and the formation of a dermal nodule. These 
melanomas were termed VGP melanomas by Clark et al (1). 
Many of these melanomas belong to the superficial spreading 
type. The scheme of melanoma progression suggested by 
Clark et al in 1989 (2), was externally validated (12,13), and 
it was demonstrated that growth phase and dermal mitosis are 
independent prognostic factors. Evidence suggests that ~45% 
of melanoma cases are entirely in an RGP, 10% have a VGP 
alone (thus classified as nodular or d'emblèe types, which are 
often amelanotic) (14), and the remaining 45% of cases present 
with a VGP tumor nodule surrounded by an RGP, in which 
they presumably arose (15). 
The present study was conducted with the aim of defining 
the ROG of these melanoma subsets. The results obtained 
indicated that in the current sample of SSMs classically 
fulfilling the clinical ABCD diagnostic criteria, two tumor 
subtypes were present: A faster growth group with a higher 
ROG, and a more indolent type group (Table I). This result 
may have relevance with regard to the consequences of diag-
nostic delay and prognosis. Previously, the calculated ROG 
values of SSMs as a whole were found to vary from 0.05 to 
0.12 mm/month (16-18); however, the heterogeneity of these 
lesions (RGP-SSMs and VGP-SSMs) was not considered.
If patients do receive a correct diagnosis, this will delay 
surgical excision and result in a worse prognosis; in our experi-
ence, the rate of growth of RGP-SSM is approximately double 
that of a VGP-SSM (0.065 vs. 0.13 mm/month). In a screening 
project for suspected nevi, there is a short time in which to 
suspect, determine or correct a diagnosis, even for SSMs if they 
escape from their RGP into a tumorigenic phase. Liu et al (4) 
observed that the ROG increases with increasing tumor thick-
ness and mitotic rate, and that a correlation was present between 
ROG and mitotic rate; however, the assessment of clinical 
features of these melanomas fulfilled the clinical criteria for a 
nodular subtype (4); by contrast, a slow ROG was associated 
with melanomas appearing to be of an SSM subtype. Although 
the ROG of the SSMs reported in the present study is not as 
high as that observed by Liu et al (4) for nodular melanomas 
(0.4-0.5 mm/month), it is equally relevant due to the implica-
tions of a possible invasive melanoma on prognosis.
The presence of mitosis has been demonstrated to be an 
independent factor associated with prognosis, and mitosis may 
be present in SSMs with a VGP (2,11). In the present study, 
SSMs with mitotic frequency of ≥1/mm2 were observed to have 
a higher Breslow's thickness and ROG compared with their 
counterparts without mitosis (Table IB). Thus, these results 
indicate that two subsets of SSM exist; the first characterized 
by the presence of mitosis and higher ROG, the second with 
a more indolent behavior and characterized by an RGP only.
Gimotty et al (19), in a study of Ki-67 expression (a marker 
of cellular proliferation), revealed that the proliferation of 
melanoma increases with the onset of tumorigenic VGP, even 
in thin invasive cutaneous melanomas, and not only in true 
nodular melanomas. The present results on the heterogeneity 
of VGP-SSMs indicate that attention must be paid to the 
subgroup with a high ROG and mitosis. The diagnostic delay 
of RGP-SSM versus VGP-SSM melanoma, with the higher rate 
of growth of the latter, may dramatically change the prognosis.
The predominant limitation of the current study was 
the anamnestic criteria used for the evaluation of the ROG, 
which remains the only method currently available to assess 
the growth speed of a melanoma. The ROG also assumes that 
tumor growth is constant and linear, and ROG cannot describe 
changing growth rate over time. Another limitation regards the 
number of patients and the high percentage of data that were 
lost (37.8%). In summary, the current study provides descrip-
tive data on the spectrum of SSMs with different ROGs and 
mitotic frequencies. Certain of these subgroups are associated 
with a relatively fast growth rate, which is lower than that of 
true nodular melanomas, but greater than that of SSMs with 
an RGP only and without the presence of mitosis. Given the 
differences in Breslow's thickness, clinicians must be aware of 
the possible diagnostic delay in the subset of melanomas that 
generally fulfill the classical ABCD clinical criteria.
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